Hongbin Yi

5PUBLICATIONS
4CO-AUTHORS
Cross-sectional analysisHaematological tumoursPredictive and prognostic markersEconomic models and forecastingInternational accounting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 28, 2026
Impacts of national volume-based procurement policy on insulin price, volume and expenditure in China: a quasi-experimental study.

|May 28, 2026
Association of haematological cancer drugs recommendation levels in Chinese Society of Clinical Oncology guideline with different approval approaches: a cross-sectional study.

|Oct 01, 2024
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States.

Hongbin Yi, Yingdan Cao, Fenghao Shi

|Jul 11, 2024
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.

Yingdan Cao, Hongbin Yi, Fenghao Shi

|Oct 18, 2023
Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.

Hongbin Yi, Fenghao Shi, Zihao Wang

Pageof 1

Frequent Collaborators

3 joint publications

Xiaoxia Wei

2 joint publications

Yingdan Cao

2 joint publications

Fenghao Shi

2 joint publications

Sheng Han